Skip to main content
OpenTrials
Completed

NCT Number: NCT02055521

Search Tolerance Signature in Vascularised Composite Allograft

Composite tissue allotransplants (CTA) involve transplantation of various tissues including vessels, nerves, skin, bones, and immune cells and entail a significant antigenic load. The large majority of recipients have been maintained on immunosuppression therapy similar to that used in solid organ transplantation that is associated with the complications usually reported in solid organ transplantation. The question whether risks associated with indefinite immunosuppressive are justified for a non-lifesaving procedure still remains unanswered. At present no CTA recipient proved to be spontaneously tolerant with any immunosuppressive protocol; indeed, until now all recipients who discontinued the immunosuppressive therapy rejected their graft. On the other hand CTA recipients showed a low incidence of chronic rejection despite the high incidence of acute rejection episodes.

For all these reasons it should be of great interest to minimize the immunosuppression in CTA patients knowing their immunologic "risk". The main outcome of this study is to search for the signature of tolerance in recipients of hand or face allotransplantation testing biomarkers previously identified in operational tolerant kidney transplant recipients.

These markers have been developed studying tolerant kidney recipients and they were already tested in five bilateral hand transplantations and one face transplantation.

The present study will include hand and face allograft recipients transplanted at least one year in several European institutions (Innsbruck, Lyon, Monza, Valencia): 11 bilateral hand transplantations, 4 single hand transplantations and 3 face transplantations. All the patients will undergo B cell phenotyping, TCR repertoire, molecular signature from operational tolerance and a skin biopsy with immunohistochemical staining of the specimens in order to show signs of acute or chronic rejection.

The results could provide a valid tool to detect operationally tolerant recipients as well as recipients prone to develop chronic rejection.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospices Civils de Lyon

Lyon, 69003, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with Hand (unilateral/bilateral) or face allotransplantation for at least one year
  • Patient without clinical sign of acute rejection at inclusion
  • Patient who signed the informed protocol consent
  • Patient older than 18 years old
  • Patient covered by an health insurance
  • Patient without legal protection

Exclusion criteria

  • Patient with Hand or face allotransplantation for less than one year
  • Patient with clinical sign of acute rejection at inclusion
  • Unsigned protocol consent
  • Patient under the age of 18 years old

Treatment and study plan

Blood sample, biopsy

Procedure

Primary outcomes

  1. Biomarkers of molecular signature from operational tolerance and/or chronic rejection research

    Time frame: 1 day

    B cell phenotyping, TCR repertoire, molecular signature from operational tolerance

Secondary outcomes

  1. Pathological characteristics of skin acute/chronic rejection on skin biopsy

    Time frame: 1 day

    skin biopsy with immunohistochemical staining of the specimens in order to show signs of acute or chronic rejection. We will try to correlate the signature of tolerance with the absence of chronic rejection symptoms, both clinically and in skin protocol biopsies.

  2. Phenotype of skin T lymphocyte in cutaneous biopsies

    Time frame: 1 day

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Collaborators

  • Hospital Clínico Universitario de Valencia
  • ISTITUTO ITALIANO CHIRURGIA DELLA MANO, Italy
  • medizinische universität innsbruck, Austria

Registry information

Acronym: BIOCTA

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Feb 5, 2014
Registry last updated
Sep 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.